Systemic antimicrobials offer an additional benefit over scaling and root planing alone in the treatment of periodontitis

Abstract

Data sources Medline, the Cochrane Oral Health Group Trials Register and EMbase were data sources. Reference lists from relevant articles were also hand-searched and a further search was made by hand of selected journals dated up to April 2001. Study selection Randomised controlled clinical trials or controlled clinical trials of at least 6 months’ duration were selected in which systemically healthy patients with either aggressive periodontitis (AgP) or chronic periodontitis (CP) were treated by scaling and root planing (SRP) plus systemic antimicrobials, or by SRP alone or with placebo, for a minimum of 6 months. Clinical attachment level (CAL) change and probing pocket depth (PPD) change were the main outcome measures. Data extraction and synthesis Information regarding quality and study characteristics was extracted independently by two reviewers. Kappa scores determined their agreement. Results were collated by drug, disease and PPD category. Data was pooled (when mean differences and standard errors were available), using either a fixed-effects or random-effects model for meta-analysis. Results A total of 25 papers were included in the analysis. Overall, SRP plus systemic antimicrobial groups demonstrated better results in CAL and PPD change than SRP alone and than placebo groups. Randomisation and allocation-concealment methods were seldom reported and blindness was usually not defined clearly. The studies showed high variability and insufficient relevant information for an adequate assessment. As a result only limited meta-analyses could be performed. These showed a statistically significant additional benefit of spiramycin (PPD change) and amoxicillin/metronidazole (CAL change) in deep pockets. Conclusions Systemic antimicrobials in conjunction with SRP can offer an additional benefit over SRP alone in the treatment of periodontitis, in terms of CAL and PPD change and reduced risk of additional CAL loss. Differences in study methodology and lack of data, however, precluded an adequate and complete pooling of data for more comprehensive analyses. It was difficult to establish definitive conclusions, although people who had greater pocket-depth, progressive or active disease, or a specific microbiological profile, may benefit more from this adjunctive therapy.